表紙
市場調查報告書

肽、大環狀相關的藥物研發服務平台的市場 (2020∼2030年)

Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030

出版商 ROOTS ANALYSIS 商品編碼 926045
出版日期 內容資訊 英文 240 Pages
商品交期: 最快1-2個工作天內
價格
肽、大環狀相關的藥物研發服務平台的市場 (2020∼2030年) Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030
出版日期: 2020年02月29日內容資訊: 英文 240 Pages
簡介

這幾年,肽(包含oligo肽,多肽,合成肽)和大環為基礎的藥理學性介入在臨床研究人員受到注目,以這些分子為焦點的藥物開發的配合措施大幅度增加。可認為是起因於前述的藥物類別所提供的高標的特異性,低毒性,良好的安全性等優點。實際上,到目前為止全世界有60種以上的肽為基礎的治療藥和大環藥物受到核可。還有現在,臨床試驗已評估有400種以上的肽系藥物,有500種以上的分子還處於開發的初期階段。

本報告提供全球肽相關及大環狀分子相關的藥物研發服務/平台的市場相關分析,系統服務概要和市場基本結構,整體市場規模趨勢預測 (2020∼2030年),各類型、各地區的詳細趨勢,主要企業的簡介,事業聯盟、資本交易的動向,未來的市場機會等資訊彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 肽/大環狀分子的概要

  • 分析概要
  • 肽醫藥品的歷史
  • 肽結構
  • 肽的主要類別
    • 二肽
    • 酯肽
    • 環狀肽/大環狀分子
    • 其他種類的肽
  • 涉及肽發現的階段
  • 肽的合成
  • 肽的修飾
  • 肽分析工具、手法
  • 肽的放出
  • 肽的用途
  • 開發藥劑中CRO (醫藥品臨床研究委外機構)的作用
  • 開發業務的外包伴隨的風險
  • 為了選擇恰當的CRO合作夥伴的重要考慮事項

第4章 服務業者的市場環境

  • 分析概要
  • 肽/大環狀相關的藥物研發服務業者:整體市場形勢
    • 各成立年度分析
    • 各企業規模分析
    • 各總公司所在地分析
    • 肽的各種類分析
    • 藥物研發各階段分析
    • 使用的肽的各生成法分析
    • 使用的肽的各修飾法分析
    • 提供的其他各類服務分析

第5章 比較分析

  • 分析概要
  • 分析方法
  • 各地區的比較分析
    • 歐洲:Peer Group I
    • 北美:Peer Group II
    • 亞太地區:Peer Group III
  • 各企業規模比較分析
    • 中小企業:Peer Group I
    • 中堅企業:Peer Group II
    • 大企業:Peer Group III
  • 結論

第6章 平台業者的市場環境

  • 分析概要
  • 肽/大環狀相關的藥物研發平台業者:整體市場形勢
    • 各成立年度分析
    • 各企業規模分析
    • 各總公司所在地分析
    • 肽的各種類分析
    • 平台的各存取模式分析

第7章 企業簡介

  • 分析概要
  • 肽/大環狀相關的藥物研發服務業者
    • GenScrip
    • JPT Peptide Technologies
    • CPC Scientific
    • IRBM
    • Creative Peptides
    • Pepscan
  • 肽/大環狀相關的藥物研發平台業者
    • Interprotein
    • RA Pharmaceuticals
    • Pepticom
    • PeptiDream
    • Creative Biolabs
    • MeSCue-Janusys

第8章 事業聯盟

  • 分析概要
  • 事業聯盟 (夥伴關係)的模式
  • 肽/大環狀相關的藥物研發平台業者:事業聯盟的一覽
    • 事業聯盟的各締結年度分析
    • 事業聯盟的各種類分析
    • 事業聯盟的各締結年度、各種類的分析
    • 肽的各種類分析
    • 各關注領域分析
    • 最活躍的企業:事業聯盟的各數量、種類的分析
    • 各地區分析

第9章 市場預測及機會分析

  • 分析概要
  • 主要的前提條件與分析方法
  • 肽藥物研發服務市場:整體分析 (2020∼2030年)
  • 肽藥物研發服務市場:肽的各類型 (2020年/2025年/2030年)
    • 合成肽
    • 生物/基因重組肽
    • 大環狀分子
  • 肽藥物研發服務市場:各藥物研發階段 (2020年/2025年/2030年)
    • 標的鑑定、檢驗
    • 安全Hit Identification
    • 領導創造
    • 先導藥物最適化
  • 肽藥物研發服務市場:各治療領域 (2020∼2030年)
    • 腫瘤性疾病
    • 代謝障礙
    • 心血管疾病
    • 感染疾病
    • 泌尿系統疾病
    • 內分泌障礙
    • 中樞神經系統 (CNS) 障礙
    • 其他的疾病
  • 肽藥物研發服務市場:各企業規模 (2020∼2030年)
    • 小規模企業
    • 中規模企業
    • 大企業
  • 肽藥物研發服務市場:各地區 (2020年/2025年/2030年)
    • 北美
    • 歐洲
    • 亞太地區

第10章 SWOT分析

  • 分析概要
  • 優勢
  • 弱點
  • 市場機會
  • 威脅
  • 結論

第11章 結論

  • 分析概要
  • 重要的要點

第12章 產業相關人員的採訪

  • 分析概要
  • 受訪者 (姓名,職位),回答內容 (概要)

第13章 附錄1:總計資料

第14章 附錄2:相關企業、組織的一覽

目錄

Overview:

Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles. , In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are currently being evaluated in clinical trials, while over 500 molecules are still in the early stages of development.

It has been reported that the overall process of drug development, from discovery of a molecule to its commercial launch, takes around 10-15 years and involves capital investments worth USD 4-10 billion. However, only a small proportion of the molecules, which are selected for further investigation during the initial stages of research, actually enter the market. Given the complexities associated with the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, the discovery of peptides and macrocycles for therapeutic use is a long, arduous and cost intensive process. As a result, many developers are opting to outsource such operations to contract research organizations (CROs) that claim to specialize in this regard. In addition, there are multiple technology platform providers, which offer licenses to proprietary peptide discovery platforms that can be used by interested drug developers / manufacturers. We believe that, as the demand for peptide-based therapeutics increases, the opportunity for contract service provides and technology developers engaged in this domain is also likely to grow in the foreseen future.

The Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030 report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. History of Peptide Drugs
  • 3.3. Structure of Peptides
  • 3.4. Major Classes of Peptides
    • 3.4.1. Dipeptides
    • 3.4.2. Depsipeptides
    • 3.4.3. Cyclic Peptides / Macrocycles
    • 3.4.4. Other Types of Peptides
  • 3.5. Steps Involved in the Discovery of Peptides
  • 3.6. Synthesis of Peptides
  • 3.7. Modification of Peptides
  • 3.8. Tools and Techniques for Peptide Analysis
  • 3.9. Delivery of Peptides
  • 3.10. Applications of Peptides
  • 3.11. Role of Contract Research Organizations (CROs) in Drug Discovery
  • 3.12. Risks Associated with Outsourcing Research Operations
  • 3.13. Key Considerations for Selecting a Suitable CRO Partner

4. MARKET LANDSCAPE OF SERVICE PROVIDERS

  • 4.1. Chapter Overview
  • 4.2. Peptides and Macrocycle Drug Discovery Service Providers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Type of Peptide
    • 4.2.5. Analysis by Drug Discovery Steps
    • 4.2.6. Analysis by Peptide Generation Method Used
    • 4.2.7. Analysis by Peptide Modification Method Used
    • 4.2.8. Analysis by Other Services Offered

5. BENCHMARK ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Benchmarking by Region
    • 5.3.1. Europe, Peer Group I
    • 5.3.2. North America, Peer Group II
    • 5.3.3. Asia Pacific, Peer Group III
  • 5.4. Benchmarking by Company Size
    • 5.4.1. Small Companies, Peer Group I
    • 5.4.2. Mid-Sized Companies, Peer Group II
    • 5.4.3. Large and Very Large Companies, Peer Group III
  • 5.5. Concluding Remarks

6. MARKET LANDSCAPE OF PLATFORM PROVIDERS

  • 6.1. Chapter Overview
  • 6.2. Peptides and Macrocycle Drug Discovery Platform Providers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Type of Peptide
    • 6.2.5. Analysis by Platform Access Model

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Peptides and Macrocycle Drug Discovery Service Providers
    • 7.2.1. GenScript
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Service Portfolio
      • 7.2.1.3. Future Outlook
    • 7.2.2. JPT Peptide Technologies
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Service Portfolio
      • 7.2.2.3. Future Outlook
    • 7.2.3. CPC Scientific
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Service Portfolio
      • 7.2.3.3. Future Outlook
    • 7.2.4. IRBM
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Service Portfolio
      • 7.2.4.3. Future Outlook
    • 7.2.5. Creative Peptides
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Service Portfolio
      • 7.2.5.3. Future Outlook
    • 7.2.6. Pepscan
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Service Portfolio
      • 7.2.6.3. Future Outlook
  • 7.3 Peptides and Macrocycle Drug Discovery Platform Providers
    • 7.3.1. Interprotein
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Peptide Discovery Platform
      • 7.3.1.3. Future Outlook
    • 7.3.2. RA Pharmaceuticals
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Peptide Discovery Platform
      • 7.3.2.3. Future Outlook
    • 7.3.3. Pepticom
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Peptide Discovery Platform
      • 7.3.3.3. Future Outlook
    • 7.3.4. PeptiDream
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Peptide Discovery Platform
      • 7.3.4.3. Future Outlook
    • 7.3.5. Creative Biolabs
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Peptide Discovery Platform
      • 7.3.5.3. Future Outlook
    • 7.3.6. MeSCue-Janusys
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Peptide Discovery Platform
      • 7.3.6.3. Future Outlook

8. PARTNERSHIPS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Peptides and Macrocycle Drug Discovery Service and Platform Providers: List of Partnerships
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Type of Peptide
    • 8.3.5. Analysis by Focus Area
    • 8.3.6. Most Active Players: Analysis by Number and Type of Partnership
    • 8.3.7. Geographical Analysis
      • 8.3.7.1. Continent-wise Distribution
      • 8.3.7.2. Country-wise Distribution

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Forecast Methodology
  • 9.3. Overall Peptide Drug Discovery Services Market, 2020-2030
  • 9.4. Peptide Drug Discovery Services Market: Analysis by Type of Peptide, 2020, 2025 and 2030
    • 9.4.1. Peptide Drug Discovery Services Market for Synthetic Peptides, 2020-2030
    • 9.4.2. Peptide Drug Discovery Services Market for Biologic and Recombinant Peptides, 2020-2030
    • 9.4.3. Peptide Drug Discovery Services Market for Macrocycles, 2020-2030
  • 9.5. Peptide Drug Discovery Services Market: Analysis by Drug Discovery Steps, 2020, 2025 and 2030
    • 9.5.1. Peptide Drug Discovery Services Market for Target Identification and Validation, 2020-2030
    • 9.5.2. Peptide Drug Discovery Services Market for Hit Identification, 2020-2030
    • 9.5.3. Peptide Drug Discovery Services Market for Lead Generation, 2020-2030
    • 9.5.4. Peptide Drug Discovery Services Market for Lead Optimization, 2020-2030
  • 9.6. Peptide Drug Discovery Services Market: Analysis by Therapeutic Area, 2020-2030
    • 9.6.1. Peptide Drug Discovery Services Market for Oncological Disorders, 2020-2030
    • 9.6.2. Peptide Drug Discovery Services Market for Metabolic Disorders, 2020-2030
    • 9.6.3. Peptide Drug Discovery Services Market for Cardiovascular Disorders, 2020-2030
    • 9.6.4. Peptide Drug Discovery Services Market for Infectious Diseases, 2020-2030
    • 9.6.5. Peptide Drug Discovery Services Market for Urological Disorders, 2020-2030
    • 9.6.6. Peptide Drug Discovery Services Market for Endocrine Disorders, 2020-2030
    • 9.6.7. Peptide Drug Discovery Services Market for CNS Disorders, 2020-2030
    • 9.6.8. Peptide Drug Discovery Services Market for Other Diseases, 2020-2030
  • 9.7. Peptide Drug Discovery Services Market: Analysis by Company Size, 2020-2030
    • 9.7.1. Peptide Drug Discovery Services Market for Small Companies, 2020-2030
    • 9.7.2. Peptide Drug Discovery Services Market for Mid-Sized Companies, 2020-2030
    • 9.7.3. Peptide Drug Discovery Services Market for Large and Very Large Companies, 2020-2030
  • 9.8. Peptide Drug Discovery Services Market: Analysis by Geography, 2020, 2025 and 2030
    • 9.8.1. Peptide Drug Discovery Services Market in North America, 2020-2030
    • 9.8.2. Peptide Drug Discovery Services Market in Europe, 2020-2030
    • 9.8.3. Peptide Drug Discovery Services Market in Asia Pacific, 2020-2030

10. SWOT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Strengths
  • 10.3. Weaknesses
  • 10.4. Opportunities
  • 10.5. Threats
  • 10.6. Concluding Remarks

11. CONCLUSION

  • 11.1. Chapter Overview
  • 11.2. Key Takeaways

12. INTERVIEW TRANSCRIPTS

  • 12.1. Chapter Overview
  • 12.2. Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
  • 12.3. Anonymous

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Historical Overview of Peptide Drugs
  • Figure 3.2 Primary Structure of Peptides
  • Figure 3.3 Secondary Structure of Peptides
  • Figure 3.4 Tertiary Structure of Peptides
  • Figure 3.6 Quaternary Structure of Peptides
  • Figure 3.7 Key Strategies for Peptide Synthesis
  • Figure 3.8 Tools and Techniques for Peptide Analysis
  • Figure 3.9 Key Considerations for Selecting a Suitable CRO Partner
  • Figure 3.10 Risks and Challenges Associated with CROs
  • Figure 4.1 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Company Size
  • Figure 4.3 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Type of Peptide
  • Figure 4.6 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Drug Discovery Steps
  • Figure 4.7 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Peptide Generation Method Used
  • Figure 4.8 Peptides and Macrocycle Service Providers: Analysis by Peptide Modification Method Used
  • Figure 4.9 Peptides and Macrocycles Service Providers: Analysis by Other Services Offered
  • Figure 5.1 Benchmark Analysis: Regional Distribution of Companies
  • Figure 5.2 Benchmark Analysis: Europe Based Companies, Peer Group I
  • Figure 5.3 Benchmark Analysis: North America Based Companies, Peer Group II
  • Figure 5.4 Benchmark Analysis: Asia Pacific Based Companies, Peer Group III
  • Figure 5.5 Benchmark Analysis: Distribution of Companies by Company Size
  • Figure 5.6 Benchmark Analysis: Small Companies, Peer Group I
  • Figure 5.7 Benchmark Analysis: Mid-Sized Companies, Peer Group II
  • Figure 5.8 Benchmark Analysis: Large and Very Large Companies, Peer Group III
  • Figure 5.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups (Based on Region)
  • Figure 5.10 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups (Based on Company Size)
  • Figure 6.1 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Year of Establishment
  • Figure 6.2 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Company Size
  • Figure 6.3 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 6.4 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 6.5 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Type of Peptide
  • Figure 6.6 Peptides and Macrocycles Drug Discovery Platform Providers: Distribution by Platform Access Model
  • Figure 7.1 GenScript: Peptide Discovery Services
  • Figure 7.2 JPT Peptide Technologies: Peptide Discovery Services
  • Figure 7.3 CPC Scientific: Peptide Discovery Services
  • Figure 7.4 IRBM: Peptide Discovery Services
  • Figure 7.5 Creative Peptides: Peptide Discovery Services
  • Figure 7.6 Pepscan: Peptide Discovery Services
  • Figure 7.7 Interprotein Corporation: Peptide Drug Discovery Platform Overview
  • Figure 7.8 RA Pharmaceuticals: Peptide Drug Discovery Platform Overview
  • Figure 7.9 Pepticom: Peptide Drug Discovery Platform Overview
  • Figure 7.10 PeptiDream: Peptide Drug Discovery Platform Overview
  • Figure 7.11 Creative Biolabs: Peptide Drug Discovery Platform Overview
  • Figure 7.12 MeSCue-Janusys: Peptide Drug Discovery Platform Overview
  • Figure 8.1 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Distribution by Year of Partnership
  • Figure 8.2 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Partnership
  • Figure 8.3 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Year-Wise Distribution by Type of Partnership
  • Figure 8.4 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Peptide
  • Figure 8.5 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Key Focus Areas
  • Figure 8.6 Peptides and Macrocycle Drug Discovery Services and Platforms: Most Active Players
  • Figure 8.7 Peptides and Macrocycle Drug Discovery Services and Platforms: Country-wise Distribution
  • Figure 8.8 Peptides and Macrocycle Drug Discovery Services and Platforms: Continent-wise Distribution
  • Figure 9.1 Overall Peptide Drug Discovery Services Market, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.2 Peptide Drug Discovery Services Market: Distribution by Type of Peptide, 2020, 2025 and 2030
  • Figure 9.3 Peptide Drug Discovery Services Market: Synthetic Peptides, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.4 Peptide Drug Discovery Services Market: Biologic and Recombinant Peptides, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.5 Peptide Drug Discovery Services Market: Macrocycles, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.6 Peptide Drug Discovery Services Market: Distribution by Drug Discovery Steps, 2020, 2025 and 2030
  • Figure 9.7 Peptide Drug Discovery Services Market: Target Identification and Validation, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.8 Peptide Drug Discovery Services Market: Hit Identification, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.9 Peptide Drug Discovery Services Market: Lead Generation, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.10 Peptide Drug Discovery Services Market: Lead Optimization, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.11 Peptide Drug Discovery Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
  • Figure 9.12 Peptide Drug Discovery Services Market: Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.13 Peptide Drug Discovery Services Market: Metabolic Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.14 Peptide Drug Discovery Services Market: Cardiovascular Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.15 Peptide Drug Discovery Services Market: Infectious Diseases, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.16 Peptide Drug Discovery Services Market: Urological Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.17 Peptide Drug Discovery Services Market: Hormonal Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.18 Peptide Drug Discovery Services Market: CNS Disorders, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.19 Peptide Drug Discovery Services Market: Other Diseases, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.20 Peptide Drug Discovery Services Market: Distribution by Company Size, 2020, 2025 and 2030
  • Figure 9.21 Peptide Drug Discovery Services Market: Small Companies, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.22 Peptide Drug Discovery Services Market: Mid-Sized Companies, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.23 Peptide Drug Discovery Services Market: Large and Very Large Companies, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.24 Peptide Drug Discovery Services Market: Distribution by Geography, 2020, 2025 and 2030
  • Figure 9.25 Peptide Drug Discovery Services Market: North America, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.26 Peptide Drug Discovery Services Market: Europe, Base Scenario, 2020-2030 (USD Million)
  • Figure 9.27 Peptide Drug Discovery Services Market: Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Figure 10.1 Peptides and Macrocycles Drug Discovery Service Providers: SWOT Analysis
  • Figure 10.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

  • Table 3.1 Key Strategies for Peptide Synthesis
  • Table 3.2 Comparison of Peptide Synthesis Processes
  • Table 4.1 List of Peptides and Macrocycle Drug Discovery Service Providers
  • Table 4.2 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Drug Discovery Steps
  • Table 4.3 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Peptide Generation Method Used
  • Table 4.4 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Peptide Modification Method Used
  • Table 4.5 Peptides and Macrocycle Drug Discovery Service Providers: Other Services
  • Table 5.1 Benchmark Analysis: Peer Groups (Region-wise)
  • Table 5.2 Benchmark Analysis: Peer Groups (Based on Company Size)
  • Table 6.1 List of Peptides and Macrocycle Drug Discovery Platform Providers
  • Table 6.2 Peptides and Macrocycle Drug Discovery Platform Providers: Information related to Types of Peptides
  • Table 6.3 Peptides and Macrocycle Drug Discovery Platform Providers: Information related to Platform Access Model
  • Table 7.1 GenScript: Company Overview
  • Table 7.2 GenScript: Future Outlook
  • Table 7.3 JPT Peptide Technologies: Company Overview
  • Table 7.4 JPT Peptide Technologies: Future Outlook
  • Table 7.5 CPC Scientific: Company Overview
  • Table 7.6 CPC Scientific: Future Outlook
  • Table 7.7 IRBM: Company Overview
  • Table 7.8 IRBM: Future Outlook
  • Table 7.9 Creative Peptides: Company Overview
  • Table 7.10 Creative Peptides: Future Outlook
  • Table 7.11 Pepscan: Company Overview
  • Table 7.12 Pepscan: Future Outlook
  • Table 7.13 Interprotein Corporation: Company Overview
  • Table 7.14 Interprotein Corporation: Future Outlook
  • Table 7.15 RA Pharmaceuticals: Company Overview
  • Table 7.16 RA Pharmaceuticals: Future Outlook
  • Table 7.17 Pepticom: Company Overview
  • Table 7.18 Pepticom: Future Outlook
  • Table 7.19 PeptiDream: Company Overview
  • Table 7.20 PeptiDream: Future Outlook
  • Table 7.21 Creative Biolabs: Company Overview
  • Table 7.22 Creative Biolabs: Future Outlook
  • Table 7.23 MeSCue-Janusys: Company Overview
  • Table 7.24 MeSCue-Janusys: Future Outlook
  • Table 8.1 Peptides and Macrocycle Drug Discovery Services and Platform Providers: List of Partnerships, 2015-2019
  • Table 13.1 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Year of Establishment
  • Table 13.2 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Company Size
  • Table 13.3 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 13.4 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 13.5 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Type of Peptide
  • Table 13.6 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Drug Discovery Steps
  • Table 13.7 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Peptide Generation Method Used
  • Table 13.8 Peptides and Macrocycle Drug Discovery Service Providers: Analysis by Peptide Modification Method Used
  • Table 13.9 Peptides and Macrocycle Drug Discovery Service Providers: Analysis by Other Services Offered
  • Table 13.10 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Year of Establishment
  • Table 13.11 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Company Size
  • Table 13.12 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 13.13 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 13.14 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Type of Peptide
  • Table 13.15 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Platform Access Model
  • Table 13.16 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Distribution by Year of Partnership
  • Table 13.17 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Partnerships
  • Table 13.18 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Year-Wise Distribution by Type of Partnerships
  • Table 13.19 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Peptide
  • Table 13.20 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Key Focus Areas
  • Table 13.21 Peptides and Macrocycle Drug Discovery Services and Platforms: Most Active Players
  • Table 13.22 Peptides and Macrocycle Drug Discovery Services and Platforms: Country-wise Distribution
  • Table 13.23 Peptides and Macrocycle Drug Discovery Services and Platforms: Continent-wise Distribution
  • Table 13.24 Overall Peptide Drug Discovery Services Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.25 Peptide Drug Discovery Services Market: Distribution by Type of Peptides, 2020, 2025 and 2030
  • Table 13.26 Peptide Drug Discovery Services Market for Synthetic Peptides, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.27 Peptide Drug Discovery Services Market for Biologic and Recombinant Peptides, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.28 Peptide Drug Discovery Services Market for Macrocycles, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.29 Peptide Drug Discovery Services Market: Distribution by Drug Discovery Steps, 2020, 2025 and 2030
  • Table 13.30 Peptide Drug Discovery Services Market for Target Identification and Validation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.31 Peptide Drug Discovery Services Market for Hit Identification, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.32 Peptide Drug Discovery Services Market for Lead Generation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.33 Peptide Drug Discovery Services Market for Lead Optimization, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.34 Peptide Drug Discovery Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
  • Table 13.35 Peptide Drug Discovery Services Market for Oncological Disorders Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.36 Peptide Drug Discovery Services Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.37 Peptide Drug Discovery Services Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.38 Peptide Drug Discovery Services Market for Infectious Diseases, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.39 Peptide Drug Discovery Services Market for Urological Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.40 Peptide Drug Discovery Services Market for Hormonal Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.41 Peptide Drug Discovery Services Market for CNS Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.42 Peptide Drug Discovery Services Market for Other Diseases, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.43 Peptide Drug Discovery Services Market: Distribution by Company Size, 2020, 2025 and 2030
  • Table 13.44 Peptide Drug Discovery Services Market for Small Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.45 Peptide Drug Discovery Services Market for Mid-Sized Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.46 Peptide Drug Discovery Services Market for Large and Very Large Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.47 Peptide Drug Discovery Services Market: Distribution by Geography, 2020, 2025 and 2030
  • Table 13.48 Peptide Drug Discovery Services Market for North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.49 Peptide Drug Discovery Services Market for Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 13.50 Peptide Drug Discovery Services Market for Asia, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3B Pharmaceuticals
  • 2. AI Squared
  • 3. AiCuris
  • 4. Aileron Therapeutics
  • 5. Alexion
  • 6. Ampersand Capital Partners
  • 7. Apigenix
  • 8. Apitope
  • 9. Asahi Kasei Pharma
  • 10. Astellas Pharma
  • 11. AstraZeneca
  • 12. Aurigene Discovery Technologies
  • 13. Bayer
  • 14. Bicycle Therapeutics
  • 15. BIND Therapeutics
  • 16. Bio-Synthesis
  • 17. Blue Ridge Biosciences
  • 18. Boehringer Ingelheim
  • 19. Bristol-Myers Squibb
  • 20. Bruker
  • 21. Cambridge Research Biochemicals
  • 22. ChemBridge
  • 23. ChemPartner
  • 24. Circle Pharma
  • 25. CMDBioscience
  • 26. CPC Scientific
  • 27. Creative Biolabs
  • 28. Creative Peptides
  • 29. Cyclenium Pharma
  • 30. Cyclogenix
  • 31. Dementia Discovery Fund
  • 32. Domainex
  • 33. Eli Lilly
  • 34. Encycle Therapeutics
  • 35. Eurofins
  • 36. Fraunhofer Institute
  • 37. EMC Microcollection
  • 38. Fujitsu
  • 39. Fundación MEDINA
  • 40. Genentech
  • 41. GenScript
  • 42. Gilead
  • 43. Grey Matter
  • 44. Gubra
  • 45. GVK BIO
  • 46. Hanmi
  • 47. Haplogen
  • 48. Heptares Therapeutics
  • 49. Interprotein Corporation
  • 50. Ipsen
  • 51. IRBM
  • 52. Isogenica
  • 53. Janssen Pharmaceuticals
  • 54. JCR Pharmaceuticals
  • 55. Jitsubo
  • 56. JPT Peptide Technologies
  • 57. Kallyope
  • 58. Kawasaki Medical School
  • 59. Kleo Pharmaceuticals
  • 60. KYORIN Pharmaceutical
  • 61. Lanthio Pharma
  • 62. Maastricht University
  • 63. Macrocyclics
  • 64. McGill University
  • 65. Menten
  • 66. MercachemSyncom
  • 67. Merck
  • 68. MeSCue-Janusys
  • 69. Mimotopes
  • 70. Morphosys
  • 71. Navigen Pharmaceuticals
  • 72. Neuland Laboratories
  • 73. New England BioGroup
  • 74. Nihon Medi-Physics
  • 75. Nimble Therapeutics
  • 76. Novartis
  • 77. Novo Nordisk
  • 78. NUMAFERM
  • 79. Nuritas
  • 80. Oncodesign
  • 81. Ono Pharmaceutical
  • 82. Orbit Discovery
  • 83. Oxford University
  • 84. Pepscan
  • 85. Pepticom
  • 86. Peptides International
  • 87. PeptiDream
  • 88. Pfizer
  • 89. Phylogica Limited
  • 90. Polyphor
  • 91. Prestwick Chemical
  • 92. Priveel Peptides
  • 93. ProteoGenix
  • 94. Provepharm Life Solutions
  • 95. Ra Pharma®
  • 96. Red Glead Discovery
  • 97. RS Synthesis
  • 98. Sanofi
  • 99. Santen Pharmaceutical
  • 100. Sapience Therapeutics
  • 101. Senn Chemicals
  • 102. Shionogi
  • 103. Smartox Biotechnology
  • 104. Sosei Group
  • 105. Taisho Pharmaceutical
  • 106. Taros
  • 107. TCG Lifesciences
  • 108. Teijin Pharma
  • 109. Thermo Fisher Scientific
  • 110. Oxurion (previously known as ThromboGenics)
  • 111. Tokyo Institute of Technology
  • 112. UCB
  • 113. UniQuest
  • 114. University of Bath
  • 115. Zealand Pharma